Molecular mechanisms and emerging therapeutics in pulmonary fibrosis: A recent update
European Journal of Pharmacology · 2025-11 · 1006 · 178159
DOI: 10.1016/j.ejphar.2025.178159 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Pharmacology, 2025-11. Verfasst von Pragati Sharma und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Banasthali Vidyapith, Banasthali, 304022, Rajasthan, India; Department of Bioscience & Biotechnology, Banasthali Vidyapith, B…. Hauptthemen laut MEDLINE: Pulmonary Fibrosis, Antifibrotic Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 135 Literaturangaben.
Abstract (Originalsprache)
Pulmonary fibrosis (PF) is a chronic, progressive, and fatal lung disorder characterized by injury to alveolar epithelial cells (AECs), the formation of activated fibroblast/myofibroblast foci, and an excessive buildup of extracellular matrix (ECM). Current treatment strategies include the administration of two main drugs, viz., pirfenidone and nintedanib. However, there is no cure for PF; thus, there is a dire need to understand the pathophysiology of PF better and identify potential novel targets for PF. This review aims to provide a recent update on the signaling pathways contributing to the intricacies of cell signaling mechanisms driving fibrogenesis, including TGF-β, Hippo-YAP, NF-κB, inflammation, and Wnt/β-catenin. Additionally, the discussion covers emerging therapeutic strategies directed against such signaling networks, focusing on some of the most promising molecular strategies to halt or reverse fibrotic processes. Additionally, we discuss preclinical studies revealing the in vitro efficacy and safety, and the current clinical status of new therapeutic agents in PF. The synergy of preclinical and clinical studies' findings will allow this review to critically evaluate current therapeutic directions and emerging trends in PF management, shaping a future course of research and clinical application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Banasthali Vidyapith, Banasthali, 304022, Rajasthan, India; Department of Bioscience & Biotechnology, Banasthali Vidyapith, Banasthali, 304022, Rajasthan, India.
- Department of Pharmacy, Banasthali Vidyapith, Banasthali, 304022, Rajasthan, India.
- Department of Internal Medicine, Division of Cardiology, LSU Health Sciences Center, Shreveport, Louisiana, USA.
- Department of Bioscience & Biotechnology, Banasthali Vidyapith, Banasthali, 304022, Rajasthan, India.
- Department of Pharmacy, Banasthali Vidyapith, Banasthali, 304022, Rajasthan, India. Electronic address: sswapnil@banasthali.in.
Zitieren
APA
Sharma, P., Kumari, K., Yadav, R., Verma, K., Paliwal, S., Paliwal, S., & Sharma, S. (2025). Molecular mechanisms and emerging therapeutics in pulmonary fibrosis: A recent update. European Journal of Pharmacology, 1006, 178159. https://doi.org/10.1016/j.ejphar.2025.178159
Vancouver
Sharma P, Kumari K, Yadav R, Verma K, Paliwal S, Paliwal S, et al. Molecular mechanisms and emerging therapeutics in pulmonary fibrosis: A recent update. European Journal of Pharmacology. 2025;1006:178159. doi:10.1016/j.ejphar.2025.178159
BibTeX
@article{Sharma2025,
author = {Sharma, Pragati and Kumari, Kajal and Yadav, Richa and Verma, Kanika and Paliwal, Swati and Paliwal, Sarvesh and Sharma, Swapnil},
title = {Molecular mechanisms and emerging therapeutics in pulmonary fibrosis: A recent update},
journal = {European Journal of Pharmacology},
year = {2025},
volume = {1006},
pages = {178159},
doi = {10.1016/j.ejphar.2025.178159}
}
EUVIMED